Lucid Diagnostics Earnings Estimate

LUCD Stock  USD 1.12  0.04  3.45%   
By analyzing Lucid Diagnostics' earnings estimates, investors can diagnose different trends across Lucid Diagnostics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Lucid Diagnostics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Lucid Diagnostics is projected to generate -0.08 in earnings per share on the 31st of March 2026. Lucid Diagnostics earnings estimates show analyst consensus about projected Lucid Diagnostics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Lucid Diagnostics' historical volatility. Many public companies, such as Lucid Diagnostics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Lucid Diagnostics' earnings estimates, investors can diagnose different trends across Lucid Diagnostics' analyst sentiment over time as well as compare current estimates against different timeframes. As of January 29, 2026, Gross Profit is expected to decline to about (3.7 M). In addition to that, Pretax Profit Margin is expected to decline to -9.9Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

Lucid Diagnostics Earnings per Share Projection vs Actual

About Lucid Diagnostics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Lucid Diagnostics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Lucid Diagnostics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Lucid Diagnostics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-183.4 M-174.2 M
Retained Earnings Total Equity-88.3 M-92.7 M
Earnings Yield(1.27)(1.20)
Price Earnings Ratio(0.82)(0.86)
Price Earnings To Growth Ratio 0.05  0.05 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.77)
Revenue Per Share
0.053
Quarterly Revenue Growth
0.033
Return On Assets
(0.79)
Return On Equity
(3.31)
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value—what Lucid Diagnostics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.